ROE yields 1.13% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, ROE + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ROE + JNJ for your $10,000?
ROE holds a portfolio of US, large- and mid-cap stocks believed to have the highest quality, valuation, dividend potential, and growth metrics across sectors. The fund aims for an equally weighted and sector-optimized portfolio. The sub-adviser's proprietary quantitative screen evaluates securities while attempting a sector-optimized selection by using metrics that vary in quality and robustness. Factors such as ROE, ROI, P/E ratio, dividend yield, projected growth estimates, and earnings momentum are considered but only metrics that best define a sector are utilized. The top 50-100 stocks based on their weighted average rank on each factor are selected. The sub-adviser monitors investments through its quantitative and systematic approach to best position the fund for changing economic trends valuations or earnings. As an actively managed fund, positions may change depending on the sub-adviser's assessment and discretion. On Apr. 22, 2024, the fund appended Equal Weight to its name.
Full ROE Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.